The new drug will inhibit two protein kinase enzymes, TBK1 and IKKe, which will suppress the growth of certain cancer cell lines.
The project aims to identify a drug candidate that is effective in disease models and would be orally well-absorbed by humans.
Domainex research director Trevor Perrior said the novel mode of action will allow the treatment of patients with drug-resistant triple-negative tumours.